1202 related articles for article (PubMed ID: 29542418)
1. Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors - A Case Series.
Sharma PV; Jobanputra YB; Lewin K; Bagatell S; Lichtstein DM
Rev Recent Clin Trials; 2018; 13(2):156-160. PubMed ID: 29542418
[TBL] [Abstract][Full Text] [Related]
2. Ketoacidosis Due to Empagliflozin, a Paradigm Shift: Case Report and Review of Literature.
Hernandez-Quiles C; Ramirez-Duque N; Acosta-Delgado D
Curr Diabetes Rev; 2019; 15(4):259-262. PubMed ID: 30047331
[TBL] [Abstract][Full Text] [Related]
3. DIABETIC KETOACIDOSIS IN PATIENTS WITH TYPE 2 DIABETES RECENTLY COMMENCED ON SGLT-2 INHIBITORS: AN ONGOING CONCERN.
Ahmed M; McKenna MJ; Crowley RK
Endocr Pract; 2017 Apr; 23(4):506-508. PubMed ID: 28437153
[TBL] [Abstract][Full Text] [Related]
4. A case series of DKA occurring in patients receiving treatment with SGLT-2 inhibitors.
Bashir J; Nalla P; Peter R; Bain SC; Chudleigh R
Diabetes Obes Metab; 2018 Jul; 20(7):1800-1801. PubMed ID: 29493069
[No Abstract] [Full Text] [Related]
5. Euglisemic diabetic ketoacidotic coma caused by dapagliflozin.
Karakaya Z; Topal FE; Topal F; Payza U; Akyol PY
Am J Emerg Med; 2018 Nov; 36(11):2136.e1-2136.e2. PubMed ID: 30150107
[TBL] [Abstract][Full Text] [Related]
6. Dapagliflozin-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus: A case report.
Lee IH; Ahn DJ
Medicine (Baltimore); 2020 May; 99(21):e20228. PubMed ID: 32481295
[TBL] [Abstract][Full Text] [Related]
7. [Diabetic euglycemic ketosis or ketoacidosis in individuals with type 2 diabetes treated by SGLT2 inhibitors: A series of Belgian clinical cases].
Menghoum N; Oriot P; Hermans MP; Mariage JL
Rev Med Interne; 2020 Apr; 41(4):226-231. PubMed ID: 31866073
[TBL] [Abstract][Full Text] [Related]
8. Euglycemic Diabetic Ketoacidosis Associated With Sodium-Glucose Cotransporter Type 2 Inhibitors in Patients With Type 2 Diabetes Mellitus Receiving Oral Therapy.
Dull RB; Spangler ML; Knezevich EL; Lau BM
J Pharm Pract; 2019 Apr; 32(2):240-243. PubMed ID: 29241389
[TBL] [Abstract][Full Text] [Related]
9. Severe euglycemic diabetic ketoacidosis of multifactorial etiology in a type 2 diabetic patient treated with empagliflozin: case report and literature review.
Sampani E; Sarafidis P; Dimitriadis C; Kasimatis E; Daikidou D; Bantis K; Papanikolaou A; Papagianni A
BMC Nephrol; 2020 Jul; 21(1):276. PubMed ID: 32669085
[TBL] [Abstract][Full Text] [Related]
10. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
Burke KR; Schumacher CA; Harpe SE
Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
[TBL] [Abstract][Full Text] [Related]
11. Euglycemic ketosis in patients with type 2 diabetes on SGLT2-inhibitor therapy-an emerging problem and solutions offered by diabetes technology.
Pfützner A; Klonoff D; Heinemann L; Ejskjaer N; Pickup J
Endocrine; 2017 Apr; 56(1):212-216. PubMed ID: 28303514
[TBL] [Abstract][Full Text] [Related]
12. Empagliflozin-Associated Euglycemic Diabtetic Ketoacidosis.
Soni P; Kumar V; Saradna A; Kupfer Y
Am J Ther; 2018; 25(6):e740-e741. PubMed ID: 29746292
[No Abstract] [Full Text] [Related]
13. Early detection of euglycemic ketoacidosis during thoracic surgery associated with empagliflozin in a patient with type 2 diabetes: A case report.
Kitahara C; Morita S; Kishimoto S; Matsuno S; Uraki S; Takeshima K; Furukawa Y; Inaba H; Iwakura H; Ariyasu H; Furuta H; Nishi M; Akamizu T
J Diabetes Investig; 2021 Apr; 12(4):664-667. PubMed ID: 32686282
[TBL] [Abstract][Full Text] [Related]
14. Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes.
Peters AL; Henry RR; Thakkar P; Tong C; Alba M
Diabetes Care; 2016 Apr; 39(4):532-8. PubMed ID: 26989182
[TBL] [Abstract][Full Text] [Related]
15. [Life-threatening ketoacidosis in a 25-year-old woman treated with sodium-glucose cotransporter 2 inhibitor].
Lindberg MJ; Kristensen FB; Yildiz A
Ugeskr Laeger; 2016 Nov; 178(47):. PubMed ID: 27908315
[TBL] [Abstract][Full Text] [Related]
16. Sodium-glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis; from Pathophysiology to Clinical Practice.
Patoulias D; Manafis A; Mitas C; Avranas K; Lales G; Zografou I; Sambanis C; Karagiannis A
Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):139-146. PubMed ID: 29412120
[TBL] [Abstract][Full Text] [Related]
17. Euglycemic diabetic ketoacidosis in type 2 diabetes with sodium glucose cotransporter 2 inhibitors.
Wang AY; Hou SK; Li SJ; Kao WF
Am J Emerg Med; 2017 Feb; 35(2):379.e5-379.e6. PubMed ID: 27614369
[No Abstract] [Full Text] [Related]
18. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study.
Ueda P; Svanström H; Melbye M; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Pasternak B
BMJ; 2018 Nov; 363():k4365. PubMed ID: 30429124
[TBL] [Abstract][Full Text] [Related]
19. Sodium-glucose cotransporter 2 inhibitors and diabetic ketoacidosis.
Bloomgarden ZT
J Diabetes; 2016 Mar; 8(2):175-6. PubMed ID: 26611882
[No Abstract] [Full Text] [Related]
20. A Case of Euglycemic Diabetic Ketoacidosis due to Empagliflozin Use in a Patient with Type 1 Diabetes Mellitus.
Bilgin S; Duman TT; Kurtkulagi O; Yilmaz F; Aktas G
J Coll Physicians Surg Pak; 2022 Jul; 32(7):928-930. PubMed ID: 35795946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
